Table 3.
Standard of Care | Alternative in Patients Who Cannot Receive Immunotherapy | |
---|---|---|
IMDC favourable risk | Nivolumab/cabozantinib Pembrolizumab/axitinib Pembrolizumab/lenvatinib |
Sunitinib Pazopanib |
IMDC intermediate and poor risk | Nivolumab/cabozantinib Pembrolizumab/axitinib Pembrolizumab/lenvatinib Nivolumab/ipilimumab |
Cabozantinib Sunitinb pazopanib |